Multiple studies substantiate the efficacy of Nobivac DP PLUS, including a 3 day onset of immunity (OOI) to protect against canine parvovirus1 and the ability to overcome parvovirus associated maternally derived antibody from 4 weeks of age2.
A group of four-week-old puppies with no pre-existing immunity were challenged with a virulent parvo 2c strain three days after vaccination with a minimal titre dose of Nobivac DP PLUS. A group of similar, unvaccinated pups were also challenged in the same manner.
Nobivac® DP PLUS demonstrated1:
A study was carried out to demonstrate the efficacy of a single vaccination of Nobivac DP PLUS when administered to four-week-old pups with moderate to high levels of maternally derived antibody (between 288-1664 HAI units) against canine parvovirus. Serological monitoring was performed to determine the effect of vaccination in the vaccinated group and to track the decline of maternally derived antibody in the control group.
Nobivac® DP PLUS demonstrated2:
100% seroconversion in the vaccinated group
With moderate-to-high levels of MDA, 100% of the vaccinated puppies mounted a serological response. This has led to the SPC wording: “Maternally derived antibodies against canine parvovirus do not interfere with the efficacy of this product.”
- Study report Nobivac DP PLUS 001, MSD Animal Health.
- Study report Nobivac DP PLUS 002, MSD Animal Health.
Nobivac® DP PLUS is a vaccine containing live attenuated canine distemper virus and live recombinant canine parvovirus. POM-V.
Further information is available from the SPC, Datasheet or package leaflet. MSD Animal Health UK Limited. Registered office Walton Manor, Walton, Milton Keynes MK7 7A J, UK. Registered in England & Wales no. 946942.
Advice should be sought from the medicine prescriber.
Use Medicines Responsibly.